InvestorsHub Logo
Followers 572
Posts 9510
Boards Moderated 1
Alias Born 09/03/2004

Re: Zardiw post# 38842

Monday, 09/10/2012 1:30:06 PM

Monday, September 10, 2012 1:30:06 PM

Post# of 49606
CTIX sure looks interesting. Three different cancer treatment trials recently announced with same product "Kevetrin". Funding provided by Dana Farber Cancer Center, Beth Israel Hospital/Pfizer and today a top 10 European Hospital/Major European Pharma. It's rare to see a small market cap biotech get fully paid clinical trials from 3 different respected Institutions aiming at three different cancer targets. Early clinical trials indicate crucial P53 enhancement is enabled by Kevetrin and lack of P53 is thought to be the key ingredient to survival in 50% of cancer cases. Dana Farber trials target cancer patients with less than 6 months to live.

No dilution to fund 3 different cancer trials is pretty impressive for a penny stock. They also have just been approved for a phase 2/3 Psoriasis treatment with another product.

Company link appears to be down right now. Possibly more info coming for the R & R conference tomorrow where managemnt will present.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.